$LALPATHLAB

Dr. Lal PathLabs is currently showcasing a massive 54-month breakout attempt, revisiting price levels not seen since January 2022. The stock has formed a powerful multi-year price action base, supported by "best-ever" fundamentals. The company recently posted a record quarterly revenue of ₹798 crore with a peak margin of 31% and a profit of ₹170 crore. Interestingly, while the stock price remained stagnant for years, the company’s profits nearly doubled, leading to a healthy P/E compression from 110 down to 52. Institutional investors (FIIs and DIIs) have been increasing their stakes, leaving a tiny 7% float with the public. View: This is a high-conviction setup. When a company posts record earnings while its stock breaks out of a four-year slumber, it usually signals a massive structural shift. For investors, this is a very positive sign; the company has finally "earned" its valuation. The combination of price breakout and fundamental backing makes it a top-tier candidate for a long-term rally.